PharmaCyte Biotech Inc (PMCB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.77M
Last updated: Nov 17, 2026 at 11:05 AM ET
PharmaCyte Biotech Inc (PMCB) Competitors
The companies most similar to PharmaCyte Biotech are CNS Pharmaceuticals (CNSP), Calidi Biotherapeutics (CLDI) and Creative Medical Technology Holdings (CELZ). By market cap, PharmaCyte Biotech ranks 8th of the 13 companies on this page; Processa Pharmaceuticals (PCSA) is the largest at $5.20M.
Peer Comparison
PMCB's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Calidi Biotherapeutics Inc. (CLDI) | $2.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Creative Medical Technology Holdings Inc (CELZ) | $4.01M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ernexa Therapeutics Inc. (ERNA) | $2.84M | N/A | N/A | 0.0% | N/A | -94.1% | 0.00% |
| Traws Pharma Inc (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Purple Biotech (PPBT) | $2.65M | N/A | N/A | 0.0% | -156.2% | 0.0% | 0.00% |
| Curis Inc (CRIS) | $2.97M | N/A | 1.6x | 0.0% | N/A | -66.0% | 0.00% |
| Bioatla Inc (BCAB) | $2.89M | N/A | N/A | 0.0% | N/A | 31.6% | 0.00% |
| Can Fite Biopharma Ltd ADR (CANF) | $4.30M | N/A | 14.3x | 0.0% | -156.8% | 0.0% | 0.00% |
| Skye Bioscience, Inc. Common Stock (SKYE) | $4.83M | N/A | N/A | 0.0% | -3685.3% | 0.0% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $3.93M | N/A | 7.9x | 0.0% | -202.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to PharmaCyte Biotech, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Calidi Biotherapeutics Inc. (CLDI) | Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. | CLDI competitors |
| Creative Medical Technology Holdings Inc (CELZ) | Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics... | CELZ competitors |
| Ernexa Therapeutics Inc. (ERNA) | Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. | ERNA competitors |
| Traws Pharma Inc (TRAW) | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. | TRAW competitors |
| Purple Biotech (PPBT) | Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United... | PPBT competitors |
| Curis Inc (CRIS) | Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. | CRIS competitors |
| Bioatla Inc (BCAB) | BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. | BCAB competitors |
| Can Fite Biopharma Ltd ADR (CANF) | Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer... | |
| Skye Bioscience, Inc. Common Stock (SKYE) | Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops... | SKYE competitors |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California. | LIMN competitors |
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
Frequently Asked Questions About PMCB
Who are PharmaCyte Biotech's main competitors?
The companies most similar to PharmaCyte Biotech include CNS Pharmaceuticals (CNSP), Calidi Biotherapeutics (CLDI), Creative Medical Technology Holdings (CELZ), Ernexa Therapeutics (ERNA) and Traws Pharma (TRAW), listed from the closest match.
Who is PharmaCyte Biotech's biggest competitor?
Processa Pharmaceuticals (PCSA) is the largest of the similar companies at $5.20M; CNS Pharmaceuticals (CNSP) is the closest match by business profile, size, sector and industry.
How does PMCB stock compare with its competitors?
PMCB's net margin is 0.0% against a peer median of 0.0%.
Which of PharmaCyte Biotech's competitors pays a higher dividend?
PharmaCyte Biotech pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is PharmaCyte Biotech bigger than its competitors?
No. PharmaCyte Biotech is 8th by market cap among the 13 companies on this page; the largest is Processa Pharmaceuticals (PCSA) at $5.20M.
PMCB pages: Overview, Earnings, Financials, Competitors